Targeting residual cardiovascular risk & vascular calcification: The clinical perspective for BET inhibition

Targeting residual cardiovascular risk  vascular calcification The clinical perspective for BET inhibition
10' education - July 3, 2019 - ERA-EDTA 2019 - Vincent Brandenburg, MD
  • Overview

    ERA-EDTA 2019 Epigenetics contribute to vascular calcification, which is a hallmark of CVD in CKD. Prof. Brandenburg explains how BET inhibition can interfere with factors and pathways associated with vascular calcification.

  • Educational information

    This lecture by prof. Vincent Brandenburg was part of a CME accredited symposium "Vascular calcification in kidney disease: Epigenetics as a novel approach?" held during ERA-EDTA 2019 in Budapest, Hungary.

  • Faculty

    Vincent Brandenburg , MD is head of the Division of Nephrology at the Rhein-Maas Klinikum in Würselen, Germany.

  • Disclosures

    This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.

  • Funding

    Funding for this educational program was provided by an unrestricted educational grant from Resverlogix.

    The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Facebook Comments


We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free